Researchers at Virginia Commonwealth University’s Massey Cancer Center and the Institute of Molecular Medicine designed a fusion superkine molecule combining interleukin-24S with interleukin-15, aiming to treat glioblastoma by targeting tumor cells and activating anti-tumor immunity simultaneously. This dual-function approach addresses the immunologically 'cold' microenvironment characteristic of glioblastoma, a highly aggressive brain cancer with poor survival outcomes. The findings, published in the Journal for ImmunoTherapy of Cancer, represent a strategic innovation to overcome tumor recurrence and immune suppression challenges in brain cancer treatment.